3 top drug consumer goods in 2020

0
144

[ad_1]

Overall, drug stocks were among the top performing names at the end of 2019.

<p class = "canvas-atom canvas-text MB (1.0em) MB (0) – SM MB (0.8em) – SM" type = "text" content = "Since October 2019 it has been iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) has risen from a low of $ 96 to almost $ 124. The SPDR S & amp; P Biotech ETF (NYSE:XBI) exploded from $ 75 to a high of $ 98.79. Even ProShares Ultra NASDAQ Biotechnology (NASDAQ:BIB) has risen from a low of $ 41 to a high of almost $ 65. "data-reactid =" 12 "> Since October 2019 the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) has risen from a low of $ 96 to almost $ 124. The SPDR S & P Biotech ETF (NYSE:XBI) exploded from $ 75 to a high of $ 98.79. Even ProShares Ultra NASDAQ Biotechnology (NASDAQ:BIB) fell from a low of $ 41 to a high of almost $ 65.

All despite concerns about possible changes in drug pricing policies ahead of the elections.

<p class = "canvas-atom canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = "InvestorPlace – Financial News, Equity Advice & amp; trading Tips"data-reactid =" 14 "> InvestorPlace – stock market news, share advice and trading tips

<p class = "Canvas-Atom-Canvas-Text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "" We have the feeling that biotech -It's investors Given the election campaigns and general macroeconomic concerns, we believe that macroeconomic problems are unlikely to have a significant fundamental impact. ” Evan Seigerman from Credit Suisse"data-reactid =" 15 ">" Although we feel that biotech investors are cautious about the election and general macroeconomic concerns by 2020, we believe that macroeconomic problems will have little fundamental impact, "says Evan Seigerman from Credit Suisse.

<p class = "canvas-atom canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = "Wedbush Analysts argue“The sector's fundamentals look good. Biotech rose in the third quarter, approvals from the Food & amp; Drug delivery is above the annual average, large cap biotech companies are attractively valued, and significant mergers and acquisitions have occurred in recent years. "" Data-reactid = "16"> Wedbush analysts argue: "The basics Biotechnology experienced a strong upswing in the third quarter, approvals by the Food & Drug Administration are above the annual average, and the assessment of large-cap biotechnologies is attractive, and there have been significant mergers and acquisitions in recent years. "

One of the biggest catalysts for future growth are the millions of retired baby boomers.

We are also seeing new, innovative treatments for a variety of problems. In addition, such stocks are recession-proof because people always need medical help.

Here are three of the best biotech stocks to see in the new year.

<h3 class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Top Drug Stocks: Destiny Therapeutics (FATE)"data-reactid =" 23 ">Top Drug Stocks: Destiny Therapeutics (FATE)

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "After fighting the gate Fate Therapeutics (NASDAQ:FATE) exploded from a low of $ 14 to $ 20 a share after positive trial results from the NK cell product candidate were released. "data-reactid =" 24 "> Fate Therapeutics (NASDAQ:FATE) exploded from a low of $ 14 to $ 20 a share after positive test results from the NK cell product candidate (Natural Kill) were released.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "In relation to data from its natural killer (NK) Cell product candidate“Current patient and donor-specific CAR T cell immunotherapies recognize only one antigen and do not take into account the significant risk of relapse due to an antigen leak. FT596 is pioneering because it is available off-the-shelf for timely patient access and enables deeper and more consistent responses by targeting multiple tumor-associated antigens, ”said Bob Valamehr, Ph.D., Chief Development Officer of Fate Therapeutics. "Data-reactid =" 25 "> With regard to the data of his candidate for natural killer cells (NK)," the current patient-specific CAR-T cell immunotherapy only recognizes an antigen and cannot address the significant risk of relapse due to antigen leakage. FT596 is pioneering because it is available off-the-shelf for timely patient access and promotes deeper and more sustained responses by targeting multiple tumor-associated antigens, ”said Bob Valamehr, Ph.D., head of development at Fate Therapeutics.

<p class = "Canvas-Atom-Canvas-Text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The company's other natural cell killer was also found Kill cancer Wells Fargo recently upgraded FATE to overweight in a patient with acute myeloid leukemia (AML) with a goal of $ 24 Kill cancer in a patient with acute myeloid leukemia (AML). Wells Fargo recently upgraded FATE to an overweight rating with a target of $ 24.

<h3 class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Axsome Therapeutics (AXSM)"data-reactid =" 28 ">Axsome Therapeutics (AXSM)

<p class = "canvas-atom canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = "Axsome Therapeutics (NASDAQ:AXSM) had an explosive year. Since January 2019, AXSM stock has exploded from a low of $ 2.64 to a recent high of $ 105.55. All after a series of important announcements throughout the year. For example, in January, AXSM found that its leading drug candidate, AXS-05 has reached its primary endpoint in a phase II trial for major depression. "data-reactid =" 29 ">Axsome Therapeutics (NASDAQ:AXSM) had an explosive year. Since January 2019, AXSM stock has exploded from a low of $ 2.64 to a recent high of $ 105.55. All after a series of important announcements throughout the year. For example, in January, AXSM found that its lead drug candidate, AXS-05, had reached its primary endpoint in a phase II study to treat major depression.

Two months later, AXSM won FDA Breakthrough Therapy for the drug. By April, the drug had also reached its primary endpoint for smoking cessation. In December, the drug AXS-12 reached its primary endpoint in a phase II study against narcolepsy.

Just two weeks ago, AXSM stock rose on reports of positive late health results for AXS-05 for treating depression.

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "" In view of the documented medical need for stronger MDD Therapies and the fact that an incredible 17 million American adults suffer from the disease every year, according to the National Institutes of Health, show that these experimental depression medications are a clear path towards blockbuster status. " Motley Fool contributor George Budwell"data-reactid =" 34 ">" Given the proven medical need for more effective MDD therapies and the fact that, according to the National Institutes of Health, 17 million American adults suffer from this disease each year, this experimental depression is well known med a clear path towards blockbuster status, ”said George Budwell, contributor to Motley Fool.

<h3 class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Pfizer (PFE)"data-reactid =" 36 ">Pfizer (PFE)

<p class = "canvas-atom canvas-text MB (1.0em) MB (0) – SM MB (0.8em) – SM" type = "text" content = "The last year was not too nice Pfizer(NYSE:PFE) or their shareholders. In late July, PFE dropped 21% as the company plans to use its blockbuster unit for drug traffickingMylan(NYSE:MYL) and announced that it was & nbsp;Lower sales and adjusted earnings forecast, "data-reactid =" 37 "> The past year has not been nice too Pfizer (NYSE:PFE) or their shareholders. At the end of July, PFE fell 21% because the company plans to combine its blockbuster drug dealer unit with PFE Mylan (NYSE:MYL) and announced that it would lower its sales and earnings forecast.

However, with a strong medication portfolio, acquisitions and an undervalued share, PFE is again of interest. The company has also just increased its dividend by 5.6%, raising the new quarterly dividend from 36 cents to be paid to shareholders on January 6, 2020, as of January 31, to 38 cents.

<p class = "canvas-atom canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = "In addition, the evaluation of the new Pfizer looks appealing In Given management's expectation that sales will grow 6% annually by 2025, which could result in 10% annual earnings per share, " notes that Barron's contributor Andrew BaryAddition, the valuation of the new Pfizer appears in light of management 's expectation that annualized sales will increase by 6% by 2025, which increases could lead to annual earnings per share of over 10%, attractive key patented drugs such as Ibrance for breast cancer and the pneumonia vaccine Prevnar, as well as a strong pipeline, ”said Barron's employee Andrew Bary.

<p class = "canvas-atom canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = "At the time of writing, Ian Cooper had no position in any of the above securities."data-reactid =" 40 ">At the time of writing, Ian Cooper had no position in any of the above securities.

More from InvestorPlace

<p class = "canvas-atom canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = "The contribution 3 top drug consumer goods in 2020 first appeared on Investor Place, "data-reactid =" 47 "> The post-3 top drug stocks of 2020 were first published on InvestorPlace.